Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
35
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,773.60 | 6.30 | -0.07% |
| CAC 40 | 7,569.61 | 11.45 | 0.15% |
| DAX 40 | 23,684.64 | 186.31 | 0.79% |
| Dow JONES (US) | 42,982.43 | 106.59 | -0.25% |
| FTSE 100 | 8,729.16 | 10.41 | 0.12% |
| HKSE | 24,325.40 | 149.27 | -0.61% |
| NASDAQ | 19,973.55 | 61.02 | 0.31% |
| Nikkei 225 | 39,584.58 | 642.51 | 1.65% |
| NZX 50 Index | 12,480.05 | 19.09 | 0.15% |
| S&P 500 | 6,092.16 | 0.02 | -0.00% |
| S&P/ASX 200 | 8,550.80 | 8.40 | -0.10% |
| SSE Composite Index | 3,448.45 | 7.52 | -0.22% |